$NBIX
NEUROCRINE BIOSCIENCES INC

2023 Q3 Form 10-Q Financial Statement

#000091447523000057 Filed on August 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $498.8M $452.7M
YoY Change 28.59% 19.7%
Cost Of Revenue $11.20M $11.50M
YoY Change 83.61% 139.58%
Gross Profit $487.6M $441.2M
YoY Change 27.71% 18.16%
Gross Profit Margin 97.75% 97.46%
Selling, General & Admin $204.2M $221.8M
YoY Change 9.61% 21.33%
% of Gross Profit 41.88% 50.27%
Research & Development $142.2M $145.8M
YoY Change 32.03% 7.28%
% of Gross Profit 29.16% 33.05%
Depreciation & Amortization $5.500M $5.100M
YoY Change 37.5% 30.77%
% of Gross Profit 1.13% 1.16%
Operating Expenses $346.4M $367.6M
YoY Change 17.82% 15.34%
Operating Profit $141.2M $73.60M
YoY Change 60.82% 34.55%
Interest Expense $1.100M $48.00M
YoY Change -8.33% 2081.82%
% of Operating Profit 0.78% 65.22%
Other Income/Expense, Net -$25.60M $48.00M
YoY Change -353.47% -161.54%
Pretax Income $115.6M $121.6M
YoY Change 18.08% -621.89%
Income Tax $32.50M $26.10M
% Of Pretax Income 28.11% 21.46%
Net Earnings $83.10M $95.50M
YoY Change 21.31% -665.09%
Net Earnings / Revenue 16.66% 21.1%
Basic Earnings Per Share $0.85 $0.98
Diluted Earnings Per Share $0.82 $0.95
COMMON SHARES
Basic Shares Outstanding 97.65M shares 97.57M shares
Diluted Shares Outstanding 101.1M shares 100.2M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.095B $976.7M
YoY Change 36.99% 50.66%
Cash & Equivalents $293.7M $160.2M
Short-Term Investments $801.4M $816.5M
Other Short-Term Assets $108.2M $100.6M
YoY Change 59.35% 60.45%
Inventory $28.80M $31.70M
Prepaid Expenses
Receivables $417.8M $387.6M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.650B $1.497B
YoY Change 36.86% 46.83%
LONG-TERM ASSETS
Property, Plant & Equipment $68.80M $149.1M
YoY Change 12.97% 123.2%
Goodwill $5.500M $5.700M
YoY Change
Intangibles $34.90M $36.90M
YoY Change
Long-Term Investments $587.5M $515.6M
YoY Change 28.42% 5.44%
Other Assets $43.10M $414.9M
YoY Change 310.48% 4049.0%
Total Long-Term Assets $1.198B $1.117B
YoY Change 27.76% 13.19%
TOTAL ASSETS
Total Short-Term Assets $1.650B $1.497B
Total Long-Term Assets $1.198B $1.117B
Total Assets $2.848B $2.613B
YoY Change 32.88% 30.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $394.9M $391.6M
YoY Change 32.61% 47.38%
Accrued Expenses $125.9M $17.70M
YoY Change 627.75% 3.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $169.9M $169.7M
YoY Change 0.41%
Total Short-Term Liabilities $691.6M $582.5M
YoY Change 42.57% 103.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $68.60M $177.6M
YoY Change 301.17% 534.29%
Total Long-Term Liabilities $68.60M $177.6M
YoY Change 301.17% 534.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $691.6M $582.5M
Total Long-Term Liabilities $68.60M $177.6M
Total Liabilities $846.1M $760.1M
YoY Change 41.3% 30.53%
SHAREHOLDERS EQUITY
Retained Earnings -$304.8M -$387.9M
YoY Change -38.52% -31.26%
Common Stock $2.309B $2.242B
YoY Change 12.37% 12.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.002B $1.853B
YoY Change
Total Liabilities & Shareholders Equity $2.848B $2.613B
YoY Change 32.88% 30.28%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $83.10M $95.50M
YoY Change 21.31% -665.09%
Depreciation, Depletion And Amortization $5.500M $5.100M
YoY Change 37.5% 30.77%
Cash From Operating Activities $212.0M $179.6M
YoY Change 114.57% 30.05%
INVESTING ACTIVITIES
Capital Expenditures $7.600M $6.800M
YoY Change 347.06% -177.27%
Acquisitions
YoY Change
Other Investing Activities -$89.70M -$119.1M
YoY Change 42.38% -396.27%
Cash From Investing Activities -$97.30M -$125.9M
YoY Change 58.73% -500.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.80M 2.900M
YoY Change 64.91% -101.05%
NET CHANGE
Cash From Operating Activities 212.0M 179.6M
Cash From Investing Activities -97.30M -125.9M
Cash From Financing Activities 18.80M 2.900M
Net Change In Cash 133.5M 56.60M
YoY Change 173.01% -152.95%
FREE CASH FLOW
Cash From Operating Activities $212.0M $179.6M
Capital Expenditures $7.600M $6.800M
Free Cash Flow $204.4M $172.8M
YoY Change 110.5% 17.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P13Y7M
CY2023Q2 us-gaap Investments
Investments
1500300000 usd
CY2022Q4 us-gaap Investments
Investments
1398600000 usd
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10400000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12000000.0 usd
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6300000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5600000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15000000.0 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
17500000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
31700000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
35100000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
5400000 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
300000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
5700000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1800000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3600000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3600000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3600000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3600000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
17200000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
160200000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163300000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
8000000.0 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7800000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
168200000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
171100000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
8200000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
8200000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
8800000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
8200000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.054
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
9100000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18500000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
15700000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16000000.0 usd
CY2023Q2 nbix Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
54400000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
130700000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23900000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
106800000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17700000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
89100000 usd
CY2023Q2 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year One
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearOne
17200000 usd
CY2023Q2 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Two
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo
33300000 usd
CY2023Q2 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Three
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree
41900000 usd
CY2023Q2 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Four
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour
43200000 usd
CY2023Q2 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced After Year Four
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour
436500000 usd
CY2022Q1 nbix Lessee Operating Lease Option Term To Construct Fifth Building
LesseeOperatingLeaseOptionTermToConstructFifthBuilding
P6Y
CY2022Q1 nbix Rent Abatement Period
RentAbatementPeriod
P10M
CY2022Q1 nbix Lessee Operating Lease Monthly Base Rent Per Square Foot
LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot
6 usd
CY2022Q1 nbix Annual Rent Escalation Percentage
AnnualRentEscalationPercentage
0.03
CY2022Q1 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 renewaloption
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q2 nbix Debt Instrument Coupon Interest
DebtInstrumentCouponInterest
1100000 usd
CY2022Q2 nbix Debt Instrument Coupon Interest
DebtInstrumentCouponInterest
1800000 usd
nbix Debt Instrument Coupon Interest
DebtInstrumentCouponInterest
2000000.0 usd
nbix Debt Instrument Coupon Interest
DebtInstrumentCouponInterest
4000000.0 usd
CY2023Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
200000 usd
CY2022Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
400000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
400000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
800000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
1300000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
2200000 usd
us-gaap Interest Expense
InterestExpense
2400000 usd
us-gaap Interest Expense
InterestExpense
4800000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
95500000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
95500000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-16900000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16900000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
18900000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
18900000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3000000.0 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3000000.0 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97600000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95600000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97400000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95400000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100300000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95400000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6700000 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12500000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5600000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12200000 shares

Files In Submission

Name View Source Status
0000914475-23-000057-index-headers.html Edgar Link pending
0000914475-23-000057-index.html Edgar Link pending
0000914475-23-000057.txt Edgar Link pending
0000914475-23-000057-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nbix-20230630.htm Edgar Link pending
nbix-20230630.xsd Edgar Link pending
nbix-20230630_def.xml Edgar Link unprocessable
nbix-20230630_g1.jpg Edgar Link pending
q2-2023xexhibit101.htm Edgar Link pending
q2-2023xexhibit311.htm Edgar Link pending
q2-2023xexhibit312.htm Edgar Link pending
q2-2023xexhibit32.htm Edgar Link pending
q2-2023xexhibit3_2.htm Edgar Link pending
q2-2023xexhibit3_2001.jpg Edgar Link pending
q2-2023xexhibit3_2002.jpg Edgar Link pending
q2-2023xexhibit3_2003.jpg Edgar Link pending
q2-2023xexhibit3_2004.jpg Edgar Link pending
q2-2023xexhibit3_2005.jpg Edgar Link pending
q2-2023xexhibit3_2006.jpg Edgar Link pending
q2-2023xexhibit3_2007.jpg Edgar Link pending
q2-2023xexhibit3_2008.jpg Edgar Link pending
q2-2023xexhibit3_2009.jpg Edgar Link pending
q2-2023xexhibit3_2010.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
nbix-20230630_pre.xml Edgar Link unprocessable
nbix-20230630_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nbix-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
nbix-20230630_lab.xml Edgar Link unprocessable